CAMP response element-binding protein interacts with and stimulates the proteasomal degradation of the nuclear receptor coactivator GRIP1

Endocrinology

Volumn 154, Issue 4, 2013, Pages 1513-1527

  Hoang, Tuyen ^a,b   Fenne, Ingvild S ^a,b   Madsen, Andre ^a,b   Bozickovic, Olivera ^a,b   Johannessen, Mona ^c   Bergsvåg, Mari ^a,b   Lien, Ernst Asbjørn ^a,b   Stallcup, Michael R ^d   Sagen, Jørn V ^a,b   Moens, Ugo ^c   Mellgren, Gunnar ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ESTROGEN RECEPTOR ALPHA; NUCLEAR RECEPTOR COACTIVATOR 2;

ARTICLE; BREAST CANCER; CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; ENZYME DEGRADATION; GENE SILENCING; IMMUNOPRECIPITATION; IN VITRO STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEASOMAL DEGRADATION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; UBIQUITINATION; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOWN-REGULATION; ESTROGEN RECEPTOR ALPHA; HUMANS; MCF-7 CELLS; NUCLEAR RECEPTOR COACTIVATOR 2; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; UBIQUITINATION;

EID: 84875830427     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-2049     Document Type: Article

References (83)

1. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 2002;108:465-474.
2. Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci U S A. 1996;93:4948-4952.
3. Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 1996;15:3667-3675.
4. Norris JD, Fan D, Stallcup MR, McDonnell DP. Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology. J Biol Chem. 1998;273:6679-6688.
5. Xu J, O'Malley BW. Molecular mechanisms and cellular biology of the steroid receptor coactivator (SRC) family in steroid receptor function. Rev Endocr Metab Disord. 2002;3:185-192.
6. York B, O'Malley BW. Steroid receptor coactivator (SRC) family: masters of systems biology. J Biol Chem. 2010;285:38743-38750.
7. Gehin M, Mark M, Dennefeld C, Dierich A, Gronemeyer H, Chambon P. The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. Mol Cell Biol. 2002;22:5923-5937.
8. Jeong JW, Lee KY, Han SJ, et al. The p160 steroid receptor coactivator 2, SRC-2, regulates murine endometrial function and regulates progesterone- independent and-dependent gene expression. Endocrinology. 2007;148:4238-4250.
9. Picard F, Gehin M, Annicotte J, et al. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell. 2002;111: 931-941.
10. Jeong JW, Kwak I, Lee KY, et al. The genomic analysis of the impact of steroid receptor coactivators (SRCs) ablation on hepatic metabolism. Mol Endocrinol. 2006;20:1138-1152.
11. Chopra AR, Louet JF, Saha P, et al. Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science. 2008;322:1395-1399.
12. Moedder UI, Monroe DG, Fraser DG, et al. Skeletal consequences of deletion of steroid receptor coactivator-2/transcription intermediary factor-2. J Biol Chem. 2009;284:18767-18777.
13. Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003;95:353-361.
14. Fleming FJ, Myers E, Kelly G, et al. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J Clin Pathol. 2004;57:1069-1074.
15. Haugan Moi LL, Hauglid Flageng M, Gandini S, et al. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. Clin Cancer Res. 2010;16:2176-2186.
16. Karmakar S, Foster EA, Smith CL. Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-α transcriptional activity. Endocrinology. 2009;150:1588-1596.
17. Karmakar S, Foster EA, Blackmore JK, Smith CL. Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line. Endocr Relat Cancer. 2011;18:113-127.
18. Girault I, Lerebours F, Amarir S, et al. Expression analysis of estrogen receptor α coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res. 2003;9:1259-1266.
19. Lopez GN, Turck CW, Schaufele F, Stallcup MR, Kushner PJ. Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity. J Biol Chem. 2001;276:22177-22182.
20. Gregory CW, Fei X, Ponguta LA, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem. 2004;279:7119-7130.
21. Frigo DE, Basu A, Nierth-Simpson EN, et al. p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Mol Endocrinol. 2006;20:971-983.
22. Chopra AR, Kommagani R, Saha P, et al. Cellular energy depletion resets whole-body energy by promoting coactivator-mediated dietary fuel absorption. Cell Metab. 2011;13:35-43.
23. Dobrovolna J, Chinenov Y, Kennedy MA, Liu B, Rogatsky I. Glucocorticoid-dependent phosphorylation of the transcriptional coregulator GRIP1. Mol Cell Biol. 2012;32:730-739.
24. Kotaja N, Karvonen U, Janne OA, Palvimo JJ. The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J Biol Chem. 2002;277:30283-30288.
25. Børud B, Hoang T, Bakke M, Jacob AL, Lund J, Mellgren G. The nuclear receptor coactivators p300/CBP/cointegrator-associated protein (p/CIP) and transcription intermediary factor 2 (TIF2) differentially regulate PKA-stimulated transcriptional activity of steroidogenic factor 1. Mol Endocrinol. 2002;16:757-773.
26. Hoang T, Fenne IS, Cook C, et al. cAMP-dependent protein kinase regulates ubiquitin-proteasome-mediated degradation and subcellular localization of the nuclear receptor coactivator GRIP1. J Biol Chem. 2004;279:49120-49130.
27. Fenne IS, Hoang T, Hauglid M, et al. Recruitment of coactivator glucocorticoid receptor interacting protein 1 to an estrogen receptor transcription complex is regulated by the 3′,5′-cyclic adenosine 5′-monophosphate-dependent protein kinase. Endocrinology. 2008; 149:4336-4345.
28. Al-Dhaheri MH, Rowan BG. Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation. Mol Endocrinol. 2007;21:439-456.
29. Fontana JA, Miksis G, Miranda DM, Durham JP. Inhibition of human mammary carcinoma cell proliferation by retinoids and intracellular cAMP-elevating compounds. J Natl Cancer Inst. 1987;78: 1107-1112.
30. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol. 2001;2: 599-609.
31. Sands WA, Palmer TM. Regulating gene transcription in response to cyclic AMP elevation. Cell Signal. 2008;20:460-466.
32. Screaton RA, Conkright MD, Katoh Y, et al. The CREB coactivator TORC2 functions as a calcium-and cAMP-sensitive coincidence detector. Cell. 2004;119:61-74.
33. Altarejos JY, Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol. 2011;12:141-151.
34. Chen D, Ma H, Hong H, et al. Regulation of transcription by a protein methyltransferase. Science. 1999;284:2174-2177.
35. Lee YH, Campbell HD, Stallcup MR. Developmentally essential protein flightless I is a nuclear receptor coactivator with actin binding activity. Mol Cell Biol. 2004;24:2103-2117.
36. Johannessen M, Delghandi MP, Seternes OM, Johansen B, Moens U. Synergistic activation of CREB-mediated transcription by forskolin and phorbol ester requiresPKCand depends on the glutaminerich Q2 transactivation domain. Cell Signal. 2004;16:1187-1199.
37. Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P, Gronemeyer H. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and-independent pathways. EMBO J. 1998;17:507-519.
38. Ma H, Hong H, Huang SM, et al. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol. 1999;19:6164-6173.
39. Huang SM, Cheng YS. Analysis of two CBP (cAMP-response-element-binding protein-binding protein) interacting sites in GRIP1 (glucocorticoid-receptor- interacting protein), and their importance for the function of GRIP1. Biochem J. 2004;382:111-119.
40. Baumann CT, Ma H, Wolford R, et al. The glucocorticoid receptor interacting protein 1 (GRIP1) localizes in discrete nuclear foci that associate with ND10 bodies and are enriched in components of the 26S proteasome. Mol Endocrinol. 2001;15:485-500.
41. Yan F, Gao X, Lonard DM, Nawaz Z. Specific ubiquitin-conjugating enzymes promote degradation of specific nuclear receptor coactivators. Mol Endocrinol. 2003;17:1315-1331.
42. Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell. 2004;116:511-526.
43. Deroo BJ, Archer TK. Proteasome inhibitors reduce luciferase and beta-galactosidase activity in tissue culture cells. J Biol Chem. 2002; 277:20120-20123.
44. Tsai HW, Katzenellenbogen JA, Katzenellenbogen BS, Shupnik MA. Protein kinase A activation of estrogen receptorα transcription does not require proteasome activity and protects the receptor from ligand-mediated degradation. Endocrinology. 2004;145:2730-2738.
45. Drabsch Y, Hugo H, Zhang R, et al. Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells. Proc Natl Acad SciUSA. 2007;104:13762-13767.
46. Collins C, Rommens JM, Kowbel D, et al. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A. 1998;95: 8703-8708.
47. Beardsley DI, Kowbel D, Lataxes TA, et al. Characterization of the novel amplified in breast cancer-1 (NABC1) gene product. Exp Cell Res. 2003;290:402-413.
48. Boulay A, Breuleux M, Stephan C, et al. The Ret receptor tyrosine kinase pathway functionally interacts with the ERα pathway in breast cancer. Cancer Res. 2008;68:3743-3751.
49. de Jager T, Pelzer T, Muller-Botz S, Imam A, Muck J, Neyses L. Mechanisms of estrogen receptor action in the myocardium. Rapid gene activation via the ERK1/2 pathway and serum response elements. J Biol Chem. 2001;276:27873-27880.
50. Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 2006;13:115-124.
51. Quinn PG. Distinct activation domains within cAMP response element-binding protein (CREB) mediate basal and cAMP-stimulated transcription. J Biol Chem. 1993;268:16999-17009.
52. Roesler WJ, Graham JG, Kolen R, Klemm DJ, McFie PJ. The cAMP response element binding protein synergizes with other transcription factors to mediate cAMP responsiveness. J Biol Chem. 1995; 270:8225-8232.
53. Johannessen M, Delghandi MP, Moens U. What turns CREB on? Cell Signal. 2004;16:1211-1227.
54. Ligumsky H, Wolf I, Israeli S, et al. The peptide-hormone glucagonlike peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res Treat. 2012;132:449-461.
55. Chhabra A, Fernando H, Watkins G, Mansel RE, Jiang WG. Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis. Oncol Rep. 2007;18:953-958.
56. Son J, Lee JH, Kim HN, Ha H, Lee ZH. cAMP-response-elementbinding protein positively regulates breast cancer metastasis and subsequent bone destruction. Biochem Biophys Res Commun. 2010;398:309-314.
57. O'Donnell KA, Keng VW, York B, et al. A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. Proc Natl Acad Sci U S A. 2012;109:E1377-E1386.
58. Ding XF, Anderson CM, Ma H, et al. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol Endocrinol. 1998;12:302-313.
59. Koh SS, Chen D, Lee YH, Stallcup MR. Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. J Biol Chem. 2001;276: 1089-1098.
60. Li H, Kim JH, Koh SS, Stallcup MR. Synergistic effects of coactivators GRIP1 and β-catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways. J Biol Chem. 2004; 279:4212-4220.
61. Huang SM, Huang CJ, Wang WM, Kang JC, Hsu WC. The enhancement of nuclear receptor transcriptional activation by a mouse actin-binding protein, alpha actinin 2. J Mol Endocrinol. 2004;32: 481-496.
62. Kotaja N, Vihinen M, Palvimo JJ, Janne OA. Androgen receptorinteracting protein 3 and other PIAS proteins cooperate with glucocorticoid receptor-interacting protein 1 in steroid receptor-dependent signaling. J Biol Chem. 2002;277:17781-17788.
63. Gianni M, Parrella E, Raska I Jr, et al. P38MAPK-dependent phosphorylation and degradation of SRC-3/AIB1 and RARα-mediated transcription. EMBO J. 2006;25:739-751.
64. Wu RC, Feng Q, Lonard DM, O'Malley BW. SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell. 2007;129:1125-1140.
65. Yi P, Feng Q, Amazit L, et al. Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1. Mol Cell. 2008;29:465-476.
66. Kim J, Jia L, Stallcup MR, Coetzee GA. The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus. J Mol Endocrinol. 2005;34:107-118.
67. MannaPR, Eubank DW, Lalli E, Sassone-Corsi P, Stocco DM. Transcriptional regulation of the mouse steroidogenic acute regulatory protein gene by the cAMP response-element binding protein and steroidogenic factor 1. J Mol Endocrinol. 2003;30:381-397.
68. Mayr BM, Canettieri G, Montminy MR. Distinct effects of cAMP and mitogenic signals on CREB-binding protein recruitment impart specificity to target gene activation via CREB. Proc Natl Acad Sci U S A. 2001;98:10936-10941.
69. Krones-Herzig A, Mesaros A, Metzger D, et al. Signal-dependent control of gluconeogenic key enzyme genes through coactivator-associated arginine methyltransferase 1. J Biol Chem. 2006;281: 3025-3029.
70. Makkonen KM, Pasonen-Seppanen S, Torronen K, Tammi MI, Carlberg C. Regulation of the hyaluronan synthase 2 gene by con-vergence in cyclic AMP response element-binding protein and retinoid acid receptor signaling. J Biol Chem. 2009;284:18270-18281.
71. Grossman SR, Deato ME, Brignone C, et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science. 2003;300:342-344.
72. Shi D, Pop MS, Kulikov R, Love IM, Kung AL, Grossman SR. CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc Natl Acad Sci U S A. 2009;106:16275-16280.
73. Manna PR, Dyson MT, Stocco DM. Role of basic leucine zipper proteins in transcriptional regulation of the steroidogenic acute regulatory protein gene. Mol Cell Endocrinol. 2009;302:1-11.
74. Conkright MD, Canettieri G, Screaton R, et al. TORCs: transducers of regulated CREB activity. Mol Cell. 2003;12:413-423.
75. Liu Y, Dentin R, Chen D, et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature. 2008; 456:269-273.
76. Song Y, Altarejos J, Goodarzi MO, et al. CRTC3 links catecholamine signalling to energy balance. Nature. 2010;468:933-939.
77. Firestein R, Feuerstein N. Association of activating transcription factor 2 (ATF2) with the ubiquitin-conjugating enzyme hUBC9. Implication of the ubiquitin/proteasome pathway in regulation of ATF2 in T cells. J Biol Chem. 1998;273:5892-5902.
78. Lassot I, Segeral E, Berlioz-Torrent C, et al. ATF4 degradation relies on a phosphorylation-dependent interaction with the SCF(βTrCP) ubiquitin ligase. Mol Cell Biol. 2001;21:2192-2202.
79. Wei Y, Jiang J, Liu D, et al. Cdc34-mediated degradation of ATF5 is blocked by cisplatin. J Biol Chem. 2008;283:18773-18781.
80. Gottlicher M, Heck S, Doucas V, et al. Interaction of the Ubc9 human homologue with c-Jun and with the glucocorticoid receptor. Steroids. 1996;61:257-262.
81. Furukawa M, Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol. 2005;25:162-171.
82. Kobayashi A, Kang MI, Okawa H, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol. 2004;24:7130-7139.
83. Isono O, Ohshima T, Saeki Y, et al. Human T-cell leukemia virus type 1 HBZ protein bypasses the targeting function of ubiquitination. J Biol Chem. 2008;283:34273-34282.